201 related articles for article (PubMed ID: 33963544)
1. The early evolutionary landscape of osteosarcoma provides clues for targeted treatment strategies.
Kovac M; Ameline B; Ribi S; Kovacova M; Cross W; Barenboim M; Witt O; Bielack S; Krieg A; Hartmann W; Nathrath M; Baumhoer D
J Pathol; 2021 Aug; 254(5):556-566. PubMed ID: 33963544
[TBL] [Abstract][Full Text] [Related]
2. Integrative genomic analysis of matched primary and metastatic pediatric osteosarcoma.
Negri GL; Grande BM; Delaidelli A; El-Naggar A; Cochrane D; Lau CC; Triche TJ; Moore RA; Jones SJ; Montpetit A; Marra MA; Malkin D; Morin RD; Sorensen PH
J Pathol; 2019 Nov; 249(3):319-331. PubMed ID: 31236944
[TBL] [Abstract][Full Text] [Related]
3. Multiregion Sequencing Reveals the Genetic Heterogeneity and Evolutionary History of Osteosarcoma and Matched Pulmonary Metastases.
Wang D; Niu X; Wang Z; Song CL; Huang Z; Chen KN; Duan J; Bai H; Xu J; Zhao J; Wang Y; Zhuo M; Xie XS; Kang X; Tian Y; Cai L; Han JF; An T; Sun Y; Gao S; Zhao J; Ying J; Wang L; He J; Wang J
Cancer Res; 2019 Jan; 79(1):7-20. PubMed ID: 30389703
[TBL] [Abstract][Full Text] [Related]
4. MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma: correlation with a dedifferentiated subtype.
Yoshida A; Ushiku T; Motoi T; Beppu Y; Fukayama M; Tsuda H; Shibata T
Am J Surg Pathol; 2012 Mar; 36(3):423-31. PubMed ID: 22301501
[TBL] [Abstract][Full Text] [Related]
5. Disruption of the TP53 locus in osteosarcoma leads to TP53 promoter gene fusions and restoration of parts of the TP53 signalling pathway.
Saba KH; Difilippo V; Kovac M; Cornmark L; Magnusson L; Nilsson J; van den Bos H; Spierings DC; Bidgoli M; Jonson T; Sumathi VP; Brosjö O; Staaf J; Foijer F; Styring E; Nathrath M; Baumhoer D; Nord KH
J Pathol; 2024 Feb; 262(2):147-160. PubMed ID: 38010733
[TBL] [Abstract][Full Text] [Related]
6. [The clonal evolution of osteosarcomas].
Baumhoer D
Pathologe; 2016 Nov; 37(Suppl 2):163-168. PubMed ID: 27651058
[TBL] [Abstract][Full Text] [Related]
7. Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine.
Subbiah V; Wagner MJ; McGuire MF; Sarwari NM; Devarajan E; Lewis VO; Westin S; Kato S; Brown RE; Anderson P
Oncotarget; 2015 Dec; 6(38):40642-54. PubMed ID: 26510912
[TBL] [Abstract][Full Text] [Related]
8. Clinical Genomic Sequencing of Pediatric and Adult Osteosarcoma Reveals Distinct Molecular Subsets with Potentially Targetable Alterations.
Suehara Y; Alex D; Bowman A; Middha S; Zehir A; Chakravarty D; Wang L; Jour G; Nafa K; Hayashi T; Jungbluth AA; Frosina D; Slotkin E; Shukla N; Meyers P; Healey JH; Hameed M; Ladanyi M
Clin Cancer Res; 2019 Nov; 25(21):6346-6356. PubMed ID: 31175097
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional Profiling Identifies the Signaling Axes of IGF and Transforming Growth Factor-b as Involved in the Pathogenesis of Osteosarcoma.
Yang R; Piperdi S; Zhang Y; Zhu Z; Neophytou N; Hoang BH; Mason G; Geller D; Dorfman H; Meyers PA; Healey JH; Phinney DG; Gorlick R
Clin Orthop Relat Res; 2016 Jan; 474(1):178-89. PubMed ID: 26463566
[TBL] [Abstract][Full Text] [Related]
10. Expression of G1 phase regulators in MG-63 osteosarcoma cell line.
Merli M; Benassi MS; Gamberi G; Ragazzini P; Sollazzo MR; Molendini L; Magagnoli G; Ferrari C; Maltarello MC; Picci P
Int J Oncol; 1999 Jun; 14(6):1117-21. PubMed ID: 10339667
[TBL] [Abstract][Full Text] [Related]
11. VS-5584 Inhibits Human Osteosarcoma Cells Growth by Induction of G1- phase Arrest through Regulating PI3K/mTOR and MAPK Pathways.
Sun JY; Hou YJ; Cui HJ; Zhang C; Yang MF; Wang FZ; Sun Z; Fan CD; Sun BL; Oh JR
Curr Cancer Drug Targets; 2020; 20(8):616-623. PubMed ID: 32286946
[TBL] [Abstract][Full Text] [Related]
12. MiR-223/Ect2/p21 signaling regulates osteosarcoma cell cycle progression and proliferation.
Xu J; Yao Q; Hou Y; Xu M; Liu S; Yang L; Zhang L; Xu H
Biomed Pharmacother; 2013 Jun; 67(5):381-6. PubMed ID: 23601845
[TBL] [Abstract][Full Text] [Related]
13. Structurally Complex Osteosarcoma Genomes Exhibit Limited Heterogeneity within Individual Tumors and across Evolutionary Time.
Rajan S; Zaccaria S; Cannon MV; Cam M; Gross AC; Raphael BJ; Roberts RD
Cancer Res Commun; 2023 Apr; 3(4):564-575. PubMed ID: 37066022
[TBL] [Abstract][Full Text] [Related]
14. Emerging next-generation sequencing-based discoveries for targeted osteosarcoma therapy.
Zhao J; Dean DC; Hornicek FJ; Yu X; Duan Z
Cancer Lett; 2020 Apr; 474():158-167. PubMed ID: 31987920
[TBL] [Abstract][Full Text] [Related]
15. Immune Infiltrate and Tumor Microenvironment Transcriptional Programs Stratify Pediatric Osteosarcoma into Prognostic Groups at Diagnosis.
Marchais A; Marques da Costa ME; Job B; Abbas R; Drubay D; Piperno-Neumann S; Fromigué O; Gomez-Brouchet A; Redini F; Droit R; Lervat C; Entz-Werle N; Pacquement H; Devoldere C; Cupissol D; Bodet D; Gandemer V; Berger M; Marec-Berard P; Jimenez M; Vassal G; Geoerger B; Brugières L; Gaspar N
Cancer Res; 2022 Mar; 82(6):974-985. PubMed ID: 35078815
[TBL] [Abstract][Full Text] [Related]
16. Silencing of Ether à go-go 1 by shRNA inhibits osteosarcoma growth and cell cycle progression.
Wu J; Zhong D; Fu X; Liu Q; Kang L; Ding Z
Int J Mol Sci; 2014 Apr; 15(4):5570-81. PubMed ID: 24694542
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneous expression and biological function of ubiquitin carboxy-terminal hydrolase-L1 in osteosarcoma.
Zheng S; Qiao G; Min D; Zhang Z; Lin F; Yang Q; Feng T; Tang L; Sun Y; Zhao H; Li H; Yu W; Yang Y; Shen Z; Yao Y
Cancer Lett; 2015 Apr; 359(1):36-46. PubMed ID: 25578779
[TBL] [Abstract][Full Text] [Related]
18. Activating GNAS mutations in parosteal osteosarcoma.
Carter JM; Inwards CY; Jin L; Evers B; Wenger DE; Oliveira AM; Fritchie KJ
Am J Surg Pathol; 2014 Mar; 38(3):402-9. PubMed ID: 24525511
[TBL] [Abstract][Full Text] [Related]
19. Osteosarcomas With Few Chromosomal Alterations or Adult Onset Are Genetically Heterogeneous.
Difilippo V; Saba KH; Styring E; Magnusson L; Nilsson J; Nathrath M; Baumhoer D; Nord KH
Lab Invest; 2024 Jan; 104(1):100283. PubMed ID: 37931683
[TBL] [Abstract][Full Text] [Related]
20. RN181 is a tumour suppressor in gastric cancer by regulation of the ERK/MAPK-cyclin D1/CDK4 pathway.
Wang S; Wang X; Gao Y; Peng Y; Dong N; Xie Q; Zhang X; Wu Y; Li M; Li JL
J Pathol; 2019 Jun; 248(2):204-216. PubMed ID: 30714150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
